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Abstract 
The human neuroblastoma cell line IMR32 produces and secretes ubstantial mounts of TRH-immunoreactivity (TRH-IR) 
as measured with radioimmunoassay (RIA) using the nonspecific antiserum 4319. It was found that synthesis of TRH-IR is 
dependent on neural differentiation: under serum-free conditions these cells exhibit neural characteristics as defined by 
morphological nd biochemical standards. After culture for 2-5 days in serum-free medium cells grew large neural processes and 
expressed neuron-specific markers whereas glial-specific markers were absent. TRH-IR became detectable after 4-8 days 
serum-free conditions. Northern blot and chromatographic analysis, however, failed to detect proTRH mRNA and authentic 
TRH in these cells. Moreover, TRH-IR was undetectable in the RIA using TRH-specific antiserum 8880. TRH-IR produced by 
differentiated cells was retained on a QAE Sephadex A-25 anion-exchange column and thus negatively charged. HPLC analysis 
showed coelution with the synthetic peptide pGlu-Glu-ProNH e. Study of the mechanisms regulating production of this novel 
peptide in these cells should further elucidate the role differentiation plays in the synthesis of neuropeptides. 
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1. Introduction 
Elucidation of the mechanisms by which the hy- 
pothalamus regulates hormone synthesis through gene 
transcription, processing and intracellular sorting of its 
prohormones necessitates a cell culture system of neu- 
ral, preferably hypothalamic origin. As yet there are no 
naturally occurring neural cell lines that produce one 
of the major hypothalamic hormones [32]. For example, 
the rat CA77 cell-line produces TRH [33] but is de- 
rived from a medullary thyroid carcinoma, and regula- 
tion of proTRH gene expression in these cells differs 
from in vivo hypothalamic regulation [16,39]. Since only 
part of the neurons producing the releasing hormones 
within the hypothalamus are hypophysiotropic (i.e. se- 
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crete their hormones in portal blood) and some of 
them are very sparse, such as LHRH producing neu- 
rons, the use of primary cultures of hypothalamic neu- 
rons necessitates large numbers of cells [32]. One way 
to overcome this is to transfect cells, known to contain 
a prohormone-processing machinery with the genomic 
DNA of the prohormone. Another approach is the use 
of targeted tumorigenesis: only in the case of LHRH 
[21] and, recently, CRH [23] did this result in immortal- 
ized hypothalamic ell lines expressing the respective 
hormones. 
Neuroblastoma cells are undifferentiated cells de- 
rived from the neural crest and have extensively been 
studied as a model of neural differentiation i  view of 
the association between maturation of human neurob- 
lastoma cells and regression of this highly malignant 
childhood tumour in vivo [1,41]. These ceils have been 
reported to produce different neuropeptides [5,26,27, 
36,37] and neurotransmitters [12,13,34] and thus consti- 
tute an alternative model for neural peptide synthesis. 
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The present study shows that these ceils produce 
TRH-like immunoreactivity dependent on neural dif- 
ferentiation. 
2. Materials and methods 
2.1. Cell cultures 
The human neuroblastoma cell line IMR32 [42] was provided by 
Dr. Versteeg (Academic Hospital Leiden, The Netherlands). Cells 
were cultured in 75 cm z flasks containing 25 ml Dulbecco's Modified 
Eagle's medium (DMEM) with 10% fetal calf serum, 500 U peni- 
cillin, 500 /~g streptomycin and 2 mM L-glutamine. At 80% conflu- 
ency (approximately 30×106 cells) the medium was changed and 
cells were grown under serum free conditions in DMEM and Ham's 
F-12 nutrient mixture (1 : 1) to induce neural differentiation. Medium 
was changed every 2-3 days. 
2.2. Radioimmunoassays nd DNA fluorimetry 
Cells were extracted in 5 ml methanol, the extract was sonicated 
and centrifuged at 2,000 × g, and the supernatant was air-dried. The 
samples were reconstituted in 0.5 ml RIA buffer and assayed for 
TRH immunoreactivity (TRH-IR) as previously described [43]. This 
assay was usually performed with antiserum 4319 (final dilution 
1:10,000) which has a low specificity for the His residue in TRH 
( < EHP-NH2). Antiserum 8880 (final dilution 1:40,000), which was 
raised in our laboratory by similar methods as used for antiserum 
4319, shows much less crossreactivity with analogs that have His 
replaced by other amino acids. Whereas the cross-reactivity of 
< EFP-NH 2 and < EEP-NH 2 in the RIA with antiserum 4319 
amounts to 100% or more, the activity is 5% and < 0.1%, respec- 
tively, in the RIA with antiserum 8880. The detection limit (defined 
as the amount of hormone that reduces binding to 90% of that 
occurring in the absence of unlabeled hormone) of the TRH assay is 
2-3 pg, and the intra- and interassay variations are between 4 and 
10%. All samples from one experiment were run in one assay. 
Medium was directly assayed without extraction. Preliminary studies 
showed that the medium did not affect antibody binding parameters 
in our RIA and that TRH and the TRH-like peptide < EEP-NH 2 
were not degraded after a 48 h incubation period in the aforemen- 
tioned media. 
The DNA content of part of the cell lysates in 0.1 N NaOH was 
determined by a fluorimetric assay using 3,5-diaminobenzoic a id 
dihydrochloride (DABA) as a fluorescent dye (Aldrich-Chemie, 
Steinheim, Germany). Samples were neutralized with 1 N HCI. A 50 
/zl portion of the neutralized sample was mixed with 50 ~1 1.5 M 
DABA and incubated for 45 min at 60°C. Subsequently, 2 ml 1 N 
Fig. 1. Morphologic characteristics of IMR32 cells during serum-free culturing. Cells were grown in serum-containing medium (A) and, 
subsequently, in serum-free medium for 5 (B), 7 (C) and 10 (D) days. Undifferentiated cells (A) consist of highly light-refractile round 
neuroblast-like cells and larger spindle-shaped fibroblast-like cells. An occasional very large vacuole-containing macrophage-like c ll can be seen. 
After 5 days of culture in serum-free medium the predominant round cells grow in tight clusters and extend thin and long processes (B). These 
processes get more numerous, thicker and longer during prolonged serum-flee culture (C and D). Note the mature neuron-like cell in C (within 
arrows). Bar (A )= 100/~m. 
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HCI was added and the fluorescence of the samples was measured 
using a Perkin Elmer fluorimeter at wavelengths of 415 nm (excita- 
tion) and 500 nm (emission). Calf thymus DNA was used as a 
standard. 
o TRH-IR • TRH-IR A DNA 
cell medium 
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2.3. Chromatography 
For chromatography, pooled medium was acidified to pH 1.8-2.0 
with trifluoracetic acid (TFA) and purified over a Sep-Pak C18 
cartridge (Waters). Care was taken to minimize contamination by 
using disposable materials whenever possible. Methanol-eluted 
TRH-IR fractions were pooled, air-dried and reconstituted in 2-4 ml 
0.05 M Tris/HCl pH 7.6, containing 0.02 M sodium azide (NAN3). 
Subsequently, samples were applied to an anion-exchange column 
(QAE Sephadex A-25; 1.5 x 10 cm) and TRH-IR was eluted in 2 ml 
fractions with a linear gradient of 50 ml 0.05 M Tris/HCl (+ NAN3) 
and 50 ml 0.5 M NaCI in 0.05 M Tris/HCl with (+NAN3). 
[125I] < EHPG ([125I]TRH-GIy) was used as a marker. Fractions were 
directly assayed in RIA and those containing TRH-IR were pooled, 
acidified with TFA and desalted over Sep-Pak C18 cartridges as 
described above. Again, the methanol fractions were pooled, air-dried 
and applied to a Vydac 218TP C18 reverse phase HPLC column 
(25 x 0.46 cm, 5 ~m particles, 300 A pore size), lsocratic elution was 
performed with 1.75% acetonitrile in 0.1% TFA at a flow rate of 1.0 
ml/min. Fractions were directly analyzed by RIA. Standards were 
added to cell culture medium and treated in the same way as 
samples obtained from the IMR32 cells. Recovery of TRH and/or  
<EEP-NH 2 over Sep-Pak, anion-exchange and HPLC columns 
amounted to 85-90%. 
2.4. Northern blot analysis 
Total RNA was extracted using the acid guanidinium phenol- 
chloroform method described by Chomczynski [7]. RNA samples 
were electrophoresed and transferred to a nylon membrane (Hy- 
bond-N +, Amersham) using routine procedures [18]. The membrane 
was hybridized with 32p-labelled cRNA (for proTRH) or cDNA 
probes as described previously [18]. cDNA probes were generated 
with random primer labelling. The generation of a proTRH cRNA 
probe is described elsewhere [18]. A pCD169 vector containing the 
2.5 kb rat neuron-specific enolase (NSE) cDNA [9] and the rat 
chromogranin B cDNA cloned in priG327 [10] were kindly provided 
by Dr. S. Forss-Petter (Research Institute of Scripps Clinic, La Jolla, 
CA). The full length mouse glial fibrillary acidic protein (GFAP) 
cDNA clone G1 in pUC [19] and the mouse 68 kDa neurofilament 
polypeptide cDNA, NF68, in pUC [20] were provided by Dr. N.J. 
Cowan (New York University, New York, NY). The pGEM-3Z 
vector containing a full length human proTRH cDNA [44] was 
provided by Dr. J.F. Wilber (University of Maryland, Baltimore, 
MD).. The rat cDNA clone p27 of brain myelin proteolipid protein 
(PLP) cloned in pUC 18 [22] was provided by Drs. R.J. Milner and 
J.G. Sutcliffe (Research Institute of Scripps Clinic, La Jolla, CA). A 
plasmid containing a 1.1 kb fragment of rat atrial peptidylglycine 
a-amidating monooxygenase (PAM-1) cDNA cloned in Bluescript SK 
[35] was provided by Dr. B.A. Eipper (Johns Hopkins University, 
Baltimore, MD). A hamster actin cDNA probe was used to correct 
for minor differences in recovery. 
3. Results 
Fig. 1 shows morphologic characteristics of cells 
grown in serum-containing medium (undifferentiated 
cells) and cells grown in serum-free medium (differen- 
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Fig. 2. Time course of cellular DNA content (p~g) and TRH-IR in 
medium (pg/day) and extracts of IMR32 neuroblastoma cells (pg) as 
determined by RIA using the nonspecific antiserum 4319. Cells were 
grown in serum-containing medium until near confluency (dO) and 
subsequently in serum-free medium for 19 days. Data represent 
means_+ S.E.M. of 4-5 flasks per time point. The detection limit of 
the RIA is depicted. The TRH-specific antiserum 8880 could not 
detect TRH-IR in medium or cells irrespective of differentiation. 
tiated ceils). Undifferentiated cells consisted of two 
morphologically distinct cell types: the predominant 
cell type was a small round highly light refractile neu- 
roblast-like cell, growing densely with focal accumula- 
tions as described previously [42]. A second cell type 
was a somewhat larger fibroblast-like and spindle- 
shaped cell growing diffusely and wide spread (Fig. 
1A). Cells grown under serum-free conditions howed 
drastic changes in morphology after 3-5 days (Fig. 1B). 
Differentiated cells stemmed from the predominant 
cell type and formed tight clusters extending long pro- 
cesses radially from the periphery and that connected 
cells together. These cells contained numerous growth 
cones. The thickness and length of the neurites was 
variable and increased uring differentiation (Fig. 1B- 
D). Morphologic differentiation - defined as increase 
in amount, length and thickness of neurites - was 
maximal after 10-12 days (Fig. 1D). 
The time-dependent change of medium TRH-IR as 
determined by RIA using the nonspecific antiserum 
4319 in medium and expressed as pg release/day, and 
cellular content of TRH-IR and DNA are depicted in 
Fig. 2. During serum-free conditions there was a grad- 
ual decline of DNA in these cells, while cellular con- 
tent and release of TRH-IR in the medium steadily 
increased. TRH-IR was first detectable after 3-5 days 
serum free culturing and showed a plateau after 12 
days. The medium contained more TRH-IR than the 
cells. TRH-IR was not detected with antiserum 8880 in 
medium or ceils (not shown) irrespective of differentia- 
tion. 
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Fig. 3. Northern blot analysis of proTRH, neuron-specific enolase 
(NSE), glial fibrillary acidic protein (GFAP), chromogranin B (ChB), 
peptidylglycine a-amidating enzyme (PAM) and actin mRNA during 
differentiation f IMR32 cells. Cells were grown in serum-containing 
medium until near confluency (dO) and subsequently in serum-free 
medium for 15 days. Total RNA was extracted on day 0, 2, 4, 7 and 
15. Lanes consist of separate samples of 20/zg RNA. Rat cortex was 
used as a control (C). The signal of PAM mRNA is only faintly 
visible. Same results were obtained in two other experiments. 
Fig. 3 shows that neuroblastoma cells expressed the 
neuron-specific marker NSE, irrespective of differenti- 
ation. As described previously [9], in rat cortex a 2.5 kb 
band was detected. The glial-specific markers GFAP, 
NF68 and PLP were not expressed in these neuroblas- 
toma cells, whereas their expression in rat cortex 
showed the mRNA signals of 2.7 kb for GFAP, 2.5 and 
4 kb for NF68 (not shown), and 3.2 and 1.6 kb for PLP 
(not shown). ProTRH mRNA could not be detected in 
these cells by Northern blot analysis. Rat cortex did 
not contain proTRH mRNA, whereas rat hypothala- 
mus contained abundant message (not shown). These 
cells also express the mRNA of PAM (4.2 kb, faintly 
visible irrespective of differentiation) and of chromo- 
granin B. The expression of the latter is dependent on 
differentiation since undifferentiated ceils do not ex- 
press this marker. After 7 and 15 days serum-free 
conditions no chromogranin B signal could be de- 
tected, but this probably was caused by low recovery 
since also the actin mRNA signal declined in these 
periods. 
To study what TRH-like peptide accounted for the 
immunoreactivity measured with the TRH-nonspecific 
antiserum 4319, we applied pooled medium from un- 
differentiated and differentiated cells to a QAE 
Sephadex A-25 anion-exchange column after purifica- 
tion on Sep-Pak C18. Fig. 4 shows that TRH-IR in 
medium from differentiated cells was totally accounted 
for by a negatively charged molecule co-eluting with 
synthetic < EEP-NH2, approximately 5 fractions be- 
fore [t25I]TRH-Gly which was used as a marker. Frac- 
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Fig. 4. Analysis of pooled medium from differentiated cells by 
anion-exchange chromatography. Cells were grown in serum-contain- 
ing medium until near confluency and subsequently in serum-free 
medium for 12 days. Pooled medium was purified on Sep-Pak C18 
columns and the subsequently pooled and air-dried methanol frac- 
tions were applied to a QAE Sephadex A-25 column. [125I]TRH-GIy 
was used as a marker. Elution positions of standards added to cell 
culture medium treated in the same way as experimental medium are 
depicted by arrows. Fractions were directly assayed by RIA with 
antiserum 4319. It is shown that TRH-IR in medium of differenti- 
ated cellls coelutes with synthetic pGlu-Glu-Pro-NH 2 ( < EEP-NH 2 
= EEP). The TRH-specific antiserum 8880 could not detect TRH-IR 
in these fractions. 
tions containing TRH-IR were pooled, purified on 
Sep-Pak C18 and analyzed on HPLC. Fig. 5 shows that 
TRH-IR again co-eluted with synthetic < EEP-NH 2. 
Media from undifferentiated cells did not contain 
TRH-IR (data not shown). 
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Fig. 5. Analysis of pooled fractions containing TRH-IR after anion- 
exchange chromatography as described in Fig. 4. Pooled fractions 
were desalted on Sep-Pak C18 columns and the subsequently pooled 
and air-dried methanol fractions were applied to a Vydac C18 
reverse phase HPLC column. Elution positions of standards are 
depicted by arrows. Fractions were directly assayed by RIA with 
antiserum 4319. It is shown that TRH-IR in the pooled fractions 
coelutes with synthetic pGlu-Glu-Pro-NH 2 (< EEP-NH 2 = EEP). 
The TRH-specific antiserum 8880 could not detect TRH-IR in these 
fractions. 
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4. Discussion 
Neuroendocrine r search of molecular mechanisms 
regulating synthesis of hypothalamic hormones is seri- 
ously hampered because of the lack of naturally occur- 
ring neural cell lines producing such hormones [32]. 
Neuroblastoma cells have the capacity to express multi- 
ple phenotypes, including neuronal, neurilemmal, and 
melanocytic haracteristics despite the fact that they 
are derived from common neuroblast progenitor cells. 
This phenomenon of coordinate biochemical and mor- 
phologic interconversion is called transdifferentiation 
and suggests that these cells are pluripotent and capa- 
ble of expressing multiple neural crest-derived pheno- 
types [1]. A particular path of differentiation is de- 
pendent on the differentiating agent used but also on 
the specific commitment of the cell to a Schwann cell, 
neuron cell or melanocytic pathway. The presence of 
NSE mRNA and the absence of GFAP, NF and PLP 
mRNAs in IMR32 cells irrespective of differentiation 
suggests that these cells are committed to a neural cell 
pathway. Neuronally-differentiated n uroblastoma cells 
have been shown to contain neurotransmitter r ceptors 
[12,24] and enzymes [12,13,41]. They produce a number 
of neurotransmitters such as dopamine, noradrenaline 
and serotonin [13], and contain noradrenergic uptake 
systems [30]. Furthermore, these cells contain neu- 
ropeptide receptors [14,29], the enzymatic machinery 
for prohormone processing [25] and neurosecretory 
organelles [13,34]. They synthesize neuropeptides such 
as enkephalins [27], VIP [5,15,37], PHM [15] and neu- 
ropeptide Y [26,36], and contain neuropeptide-degrad- 
ing enzymes [45]. Since the ubiquitous TRH is also 
located in neural crest derivatives like the spinal cord 
[2] and the adrenal gland [38], we hypothesized that 
differentiated neuroblastoma cells might produce TRH 
and thus constitute a model of neural proTRH gene 
expression. These cells, however, do not express the 
proTRH gene since we could not detect TRH-IR with 
our TRH-specific antiserum 8880, and Northern blot 
analysis failed to reveal the presence of proTRH 
mRNA in these cells. Also in situ hybridization analy- 
sis could not detect proTRH mRNA in IMR32, irre- 
spective of differentiation (J.M.M. Rondeel, personal 
observation). Analysis by anion-exchange chromatogra- 
phy revealed that these cells produce a negatively 
charged TRH-like peptide coeluting with synthetic 
pGlu-Glu-ProNH 2 (< EEP-NH2). This finding was 
confirmed by a second chromatographic analysis using 
reverse phase HPLC. Although only amino acid analy- 
sis can reveal the exact nature of the TRH-like pep- 
tide, from our chromatographic and RIA data we can 
draw several conclusions. Firstly, because of the nature 
of antigen recognition of our TRH antisera, the TRH- 
like peptide has to be C-terminally amidated and N- 
terminally cyclized. Secondly, retention of the TRH-like 
peptide during anion-exchange chromatography con- 
firms its negative charge. Since the middle amino acid 
residue determines the overall charge of this tripep- 
tide, its structure has to be pGlu-Glu-ProNH 2 or 
pGlu-Asp-ProNH 2, which has not been characterized 
before. Coelution with synthetic pGlu-Glu-ProNH 2 in 
two different chromatographic systems strongly sug- 
gests that this tripeptide accounts for TRH-IR pro- 
duced by these cells. In addition, synthetic pGlu-Asp- 
ProNH 2 (courtesy of Dr. W.J.A. Boersma, TNO, Ri- 
jswijk, The Netherlands) does not crossreact in RIA 
with antiserum 4319, whereas its retention time on 
HPLC differs from that of pGlu-Glu-ProNH 2 (unpub- 
lished). 
Production of pGlu-Glu-ProNH 2 is dependent on 
differentiation grade. Differentiation characteristics in- 
clude morphological, biochemical and electrophysiolog- 
ical parameters. Neurally differentiated cells show a 
typically neural-like appearance [12,34,41], express 
neuron-specific markers, while glial-specific markers 
are absent (present study) and behave as neurons in 
electrophysiologic studies [1,12]. The production of 
neuropeptides and the expression of chromogranin B 
mRNA [10] can be viewed as another characteristic of
neuroendocrine differentiation. Interestingly, there is a 
good correlation between morphological differentia- 
tion and production of the TRH-like peptide by these 
cells. Peptide production is first detectable during ini- 
tial differentiation (day 3-5) and shows a plateau when 
differentiation characteristics are maximal (day 12). In 
only one other study was neutral or acidic TRH-IR 
localized in the nervous system, principally in the hip- 
pocampus, brain stem and dorsal colliculi but the exact 
nature of the TRH-IR was not further characterized 
[31]. A recent report showed the presence of TRH-IR 
in human benign prostate hyperplasia, while in prostate 
cancer no TRH-IR could be detected [11]. Again, these 
latter findings imply that the presence or absence of 
TRH-IR is dependent on differentiation grade. 
Since TRH-like peptides are C-terminally amidated 
it is obvious that their production is also dependent on 
the presence of an a-amidating enzyme. Indeed, these 
cells express the mRNA of PAM and its expression is 
irrespective of differentiation. 
The TRH-like peptide pGlu-Glu-ProNH 2 is present 
in the pituitary [3] and the genital tract [4]. A recent 
study suggests that it might influence motility of sper- 
matozoa [40]. As yet its precise function and biological 
significance, however, are unknown, although the pres- 
ence of a C-terminally amidated ProNH 2 points to 
biological activity [8]. Its TRH-like appearance causes 
it to crossreact with a number of antisera that are 
being used in RIA, since most of these antisera react 
specifically with the N-terminal pGlu and the C-termi- 
nal ProNH2 and are less specific for the His residue. 
Therefore, most of the TRH-IR found in the prostate 
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can be attributed to pGlu-Glu-ProNH 2 [4]. It should 
be mentioned, however, that this is the only reason to 
call this peptide TRH-like: the proTRH gene lacks 
codons that could give rise to pGlu-Glu-ProNH 2 [17] 
and this novel tripeptide is unlikely to interact with the 
TRH receptor because of its negative charge at physio- 
logic pH [28]. 
Our two antisera, of which one is TRH-specific and 
the other nonspecific and reacting with any tripeptide 
pGlu-X-ProNH2, should forward the study of the local- 
ization and biological significance of TRH-like pep- 
tides. Furthermore, molecular mechanisms regulating 
pGlu-Glu-ProNH 2 synthesis can now be studied in 
neuroblastoma cells dependent on a well-defined bio- 
logical process like neural differentiation. Mechanisms 
regulating neural differentiation and thus production 
of neuropeptides may be extrapolated to other cells, 
e.g. hypothalamic neurons, to establish cell culture 
systems producing hypothalamic hormones. Indeed, we 
recently reported that the differentiating agent 
bromo-deoxy-uridine that is known to induce differen- 
tiation in neuroblastoma cells [12], markedly enhances 
production of TRH in fetal hypothalamic neurones in 
primary culture [6]. 
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